151 related articles for article (PubMed ID: 38578580)
1. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status.
Schubert L; Mbekwe-Yepnang AM; Wassermann J; Braik-Djellas Y; Jaffrelot L; Pani F; Deniziaut G; Lussey-Lepoutre C; Chereau N; Leenhardt L; Bernier MO; Buffet C
J Endocrinol Invest; 2024 Jun; 47(6):1573-1581. PubMed ID: 38578580
[TBL] [Abstract][Full Text] [Related]
2. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Meng C; Song J; Long W; Mu Z; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2023; 14():1109439. PubMed ID: 36843580
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
4. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
6. Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas.
Li G; Lei J; Song L; Jiang K; Wei T; Li Z; Gong R; Zhu J
Cancer Med; 2018 Nov; 7(11):5448-5456. PubMed ID: 30264548
[TBL] [Abstract][Full Text] [Related]
7. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
Wang C; Zhang X; Li H; Li X; Lin Y
PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
[TBL] [Abstract][Full Text] [Related]
8. Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis.
Parvathareddy SK; Siraj AK; Siraj N; Ahmed SO; Al-Rasheed M; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2024; 15():1326976. PubMed ID: 38812819
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound characteristics of cervical lesions in patients with radioiodine refractory differentiated thyroid cancer: A strobe-compliant article.
Gao L; Lin Y; Jiang Y; Li H; Gao Q; Xi X; Wang Y; Yang X; Lai X; Zhu S; Zhang X; Zhao R; Zhang B
Medicine (Baltimore); 2019 Nov; 98(45):e17876. PubMed ID: 31702656
[TBL] [Abstract][Full Text] [Related]
10. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
[TBL] [Abstract][Full Text] [Related]
11. Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer.
Cheng X; Xu S; Zhu Y; Wu J; Bao J; Yu H; Zhang L
Eur J Clin Invest; 2022 Apr; 52(4):e13721. PubMed ID: 34855206
[TBL] [Abstract][Full Text] [Related]
12. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract][Full Text] [Related]
13. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
14. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J; Liu Z; Su Y; Peng X; Xie Y
Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
[TBL] [Abstract][Full Text] [Related]
16. Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features.
Lorusso L; Minaldi E; Esposito G; Piaggi P; Bottici V; Brogioni S; Giani C; Valerio L; Molinaro E; Elisei R; Agate L
J Endocrinol Invest; 2023 Oct; 46(10):2165-2173. PubMed ID: 37084131
[TBL] [Abstract][Full Text] [Related]
17.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
18. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
20. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.
Zhang XY; Sun JW; Qiu ZL; Wang Y; Chen XY; Zhao JH; Luo QY
Endocrine; 2019 Nov; 66(2):254-265. PubMed ID: 31317522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
